Beyond Sequencing – Agena Bioscience to Present Novel MassArray-based Cancer Diagnostics at ESMO 2016


Monday, September 26, 2016

Agena Bioscience will present its novel, MassArray-based cancer diagnotics at ESMO 2016. A special goody for journalists is available upon request – please contact us at info(at)akampion.com.

Activities at the ESMO 2016 Congress

Visit Agena in Copenhagen to learn how you can combine high sensitivity, accuracy, reliability, and data quality for improved patient management. View customers’ posters, attend Agena´s Investigator Studio presentation, stop by booth #205, or schedule a meeting with Agena directly.

Oral Lecture (Poster)
Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
Friday, October 7th: 17:00 – 17:15
Presenter: Ed Schwalbe, Newcastle University, UK

Investigator Studio
Clinical Rationale for EGFR T790M Testing in Circulating Tumour DNA
Saturday, October 8th: 16:00 – 16:30
Kiev lecture room

Company News: iOmx Therapeutics raises EUR 40 million in Series A round


Thursday, September 22, 2016

- Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced the closing of a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.

iOmx focuses on the development of first-in-class cancer therapeutics addressing next-generation immune checkpoints. By systematically screening human tumor cells, the company has already identified a number of new targets and analyzed their mode of action. The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.

Company News: ISA Pharmaceuticals’ CSO Prof. Cornelis Melief to Present at CRI-CIMT-EATI-AACR Meeting in New York City


Wednesday, September 21, 2016

- Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO, will jointly chair “Plenary Session 1: Antigens and Vaccines” on September 25, 2016, 8:50 am – 12:00 pm EST at the upcoming CRI-CIMT-EATI-AACR Meeting in New York City.

During the session, Melief will give a presentation titled “Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination”, outlining recent progress in the field.

Company News: Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens


Wednesday, September 7, 2016

- Agreement gives Curetis worldwide rights to database and IP based on Next Generation Sequencing

- GEAR significantly enhances Curetis’ leading position in the area of genetic antimicrobial resistance biomarker testing

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the signing of an asset acquisition agreement with the Siemens Technology Accelerator GmbH (STA). Under the terms of the agreement, Curetis has acquired sole commercial rights from STA to the GEAR GEnetic Antibiotic Resistance and Susceptibility platform and database with all its content, numerous GEAR-related patents and patent applications, as well as all corresponding know-how. The deal gives Curetis sole worldwide product development and commercial rights, including the right to sublicense in the fields of human and animal diagnostics as well as food safety testing. Furthermore, Curetis has secured the sole rights to leverage the GEAR assets in collaboration with pharmaceutical companies for the development of novel antimicrobial drugs for human and animal health.

Company News: Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge


Tuesday, September 6, 2016

- Launch follows successful completion of CE Performance Evaluation Study

- ITI now covers 102 diagnostic targets, including 85 pathogens and 17 resistance markers

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the successful completion of the CE Performance Evaluation study of the next generation of its Unyvero ITI Implant and Tissue Infection Application Cartridge (Unyvero ITI).

The new Unyvero ITI comes with an extended panel and increased sensitivity. It will be launched in the third quarter of 2016 as a CE-IVD-marked product in the European direct sales and international distribution markets. Unyvero ITI is designed for the diagnosis of many types of severe infections, including prosthetic joint infections, surgical site infections, catheter-associated infections and skin and soft tissue infections.